MedTrace Logo

superDimension™ Navigation System Version 7.2 With Fluoroscopic Navigation Technology

NCT03585959 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2020-04-29

Study results available
· View outcomes & findings →

Summary

The purpose of this investigation is to confirm the clinical accuracy of the superDimension™ Navigation System Version 7.2 with Fluoroscopic Navigation Technology.

Conditions

Interventions

DEVICE

superDimension™ Navigation System Version 7.2

superDimension™ Navigation System Version 7.2 with Fluoroscopic Navigation Technology in subjects undergoing lung lesion biopsy

Sponsors & Collaborators

  • Medtronic - MITG

    lead INDUSTRY

Principal Investigators

  • Michael A. Pritchett, DO MPH · FirstHealth Moore Regional Hospital

  • Krishnendu Bhadra, MD · CHI Memorial Medical Group

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-03
Primary Completion
2019-02-13
Completion
2019-02-18
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03585959 on ClinicalTrials.gov